A Study of LY3473329 in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

April 7, 2022

Study Completion Date

April 7, 2022

Conditions

Healthy

Interventions

DRUG

LY3473329

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

Altasciences Clinical Los Angeles, Inc, Cypress

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT05038787 - A Study of LY3473329 in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter